{"title":"难治性/复发性淋巴瘤患者CD19 CAR - T治疗后继发性骨髓增生异常综合征","authors":"Cancan Lu, Ming-Zhe Zhao","doi":"10.7754/Clin.Lab.2024.240910","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although several chimeric antigen receptor T cells (CAR T) targeting CD19 are curative for patients with relapsed/refractory(R/R) B-cell lymphoma, but the clinical safety and efficacy of this CAR T therapy remain unclear. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T therapy.</p><p><strong>Methods: </strong>A patient with R/R follicular lymphoma was diagnosed with secondary myelodysplastic syndrome (s-MDS) after CD19 CAR T therapy. We also provided a review of recently published literature concerning the risk of secondary myeloid neoplasms (SMN) following CAR T therapy.</p><p><strong>Results: </strong>The patient had secondary MDS after CD19 CAR T therapy. She received active treatment for nearly one year and then she died.</p><p><strong>Conclusions: </strong>The case illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma and provides useful information of this uncommon later event.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 2","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma.\",\"authors\":\"Cancan Lu, Ming-Zhe Zhao\",\"doi\":\"10.7754/Clin.Lab.2024.240910\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Although several chimeric antigen receptor T cells (CAR T) targeting CD19 are curative for patients with relapsed/refractory(R/R) B-cell lymphoma, but the clinical safety and efficacy of this CAR T therapy remain unclear. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T therapy.</p><p><strong>Methods: </strong>A patient with R/R follicular lymphoma was diagnosed with secondary myelodysplastic syndrome (s-MDS) after CD19 CAR T therapy. We also provided a review of recently published literature concerning the risk of secondary myeloid neoplasms (SMN) following CAR T therapy.</p><p><strong>Results: </strong>The patient had secondary MDS after CD19 CAR T therapy. She received active treatment for nearly one year and then she died.</p><p><strong>Conclusions: </strong>The case illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma and provides useful information of this uncommon later event.</p>\",\"PeriodicalId\":10384,\"journal\":{\"name\":\"Clinical laboratory\",\"volume\":\"71 2\",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical laboratory\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7754/Clin.Lab.2024.240910\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240910","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：虽然几种靶向CD19的嵌合抗原受体T细胞（CAR - T）可以治愈复发/难治性（R/R） b细胞淋巴瘤患者，但这种CAR - T疗法的临床安全性和有效性尚不清楚。继发性恶性肿瘤的风险，特别是髓系肿瘤，是CAR - T治疗中特别关注的问题。方法：1例R/R滤泡性淋巴瘤患者经CD19 CAR - T治疗后诊断为继发性骨髓增生异常综合征（s-MDS）。我们还回顾了最近发表的关于CAR - T治疗后继发性髓系肿瘤（SMN）风险的文献。结果：患者经CD19 CAR - T治疗后出现继发性MDS。她接受了将近一年的积极治疗，然后去世了。结论：该病例说明了R/R b细胞淋巴瘤患者在CD19 CAR - T治疗后SMN的发生和进展，并为这一罕见的后期事件提供了有用的信息。
Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma.
Background: Although several chimeric antigen receptor T cells (CAR T) targeting CD19 are curative for patients with relapsed/refractory(R/R) B-cell lymphoma, but the clinical safety and efficacy of this CAR T therapy remain unclear. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T therapy.
Methods: A patient with R/R follicular lymphoma was diagnosed with secondary myelodysplastic syndrome (s-MDS) after CD19 CAR T therapy. We also provided a review of recently published literature concerning the risk of secondary myeloid neoplasms (SMN) following CAR T therapy.
Results: The patient had secondary MDS after CD19 CAR T therapy. She received active treatment for nearly one year and then she died.
Conclusions: The case illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma and provides useful information of this uncommon later event.
期刊介绍：
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
